Vertex Pharmaceuticals (VRTX) received a significant boost as Health Canada's approval of ALYFTREK marked a vital step in expanding cystic fibrosis treatment options. This approval and other successes ...

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $470.13, denoting a +2.54% move from the preceding trading day.

Buying $1000 In VRTX: If an investor had bought $1000 of VRTX stock 10 years ago, it would be worth $3,509.46 today based on a price of $459.81 for VRTX at the time of writing.

Detailed price information for Vortex Energy Corp. (VRTX-CN) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals (VRTX) announced that Health Canada has granted Marketing Authorization for ALYFTREK, a new triple combination therapy for ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals Inc. closed 10.89% short of its 52-week high of $519.88, which the company achieved on November 8th.

Vertex Pharmaceuticals Inc. closed 9.68% short of its 52-week high of $519.88, which the company reached on November 8th.

Key Points Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals all have important ongoing clinical trials. Shares of these drugmakers could jump if the data from the studies is positive.All ...

Tech français consacré aux nouvelles technologies (internet, logiciel, matériel, mobilité, entreprise) et au jeu vidéo PC et consoles.

GreensKeeper stays cautious amid frothy markets, betting on long-term value. Learn how disciplined investing can thrive when ...

Davenport’s Q2 results beat the benchmark as AI winners and infrastructure plays led gains. See how stock discipline and ...